July 12, 2021 07:47 AM EDT
Deals

Branch­ing out from di­a­betes? No­vo Nordisk shells out the big bucks for Prothena's AT­TR amy­loi­do­sis pipeline

Max Gelman

Senior Editor

Os­ten­si­bly look­ing to branch out from its di­a­betes fran­chis­es, No­vo Nordisk is mak­ing a ma­jor play in­to the amy­loid space — and pay­ing a pret­ty pen­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

A service from the Financial Times